Business Wire

ALTER-DOMUS

19.7.2022 09:02:07 CEST | Business Wire | Press release

Share
Leading Fund Administrator Alter Domus Appoints Gus Harris to its Group Executive Board

Alter Domus, a leading provider of integrated solutions for the alternative investment industry, today announced it has appointed Gus Harris, Head of AD Data & Analytics, to its Group Executive Board (GEB) where he will continue to report to Doug Hart, Chief Executive Officer.

In his current role, Gus leads Alter Domus’ data and analytics products strategy and team, developing new data assets and offerings to provide value-add solutions to alternatives market participants, including risk managers, investment managers, analysts and support functions at investor and asset manager clients. The team will help clients bring their data into a modern technology-enabled environment, allowing them to develop a competitive edge in their ability to efficiently generate meaningful and timely insights from their most crucial data sets.

As an extension to our data and analytics efforts, Gus is overseeing the development of proprietary applications into Software-as-a-Service (SaaS) products, which will further expand Alter Domus’ reach into the middle and front offices of their expanding client base. Early product development has focused on solutions which improve operational governance and efficiency for clients to more effectively risk-manage, monitor and grow their alternatives portfolios. The team has lined up several clients, including new clients, and strategic partnerships to accelerate their go-to-market and will have several newly built products by year-end.

Since joining Alter Domus last October, Gus has hired a world-class team to oversee the firm’s growth in this important area. The seasoned team, which has extensive experience building similar solutions for large financial institutions globally, brings together significant capabilities around modern big data, data science, technology, and product management disciplines. Team members have honed their skills at, and joined Alter Domus directly from, reputable institutions such as Amazon Web Services, Morgan Stanley, Moody’s Analytics, KPMG, and other established multinational organizations.

“Technology has been an integral part of the backbone of Alter Domus’ offering to clients, and Gus has brought an innovative and forward-thinking vision to our data and analytics services. Clients are under increasing pressure to better manage and exploit data, which makes Gus’ voice and perspective at a group executive level particularly important,” said Doug Hart . “Gus brings a strong sense of leadership, collegiality, and considerable expertise to our leadership team, key traits which have helped to catalyze his team’s growth and offering in a relatively short period of time.”

“I am proud to join Alter Domus’ group executive board, and I look forward to partnering with this talented and dynamic group of executive leaders. Alter Domus’ data and analytics team, which is comprised of seasoned and proven industry professionals, is undergoing tremendous growth and is already engaging with leading general and limited partners in the private equity, private debt – including CLO managers and investors – and commercial real estate sectors on complex and important projects,” said Gus Harris . “This reflects the increasingly important role that data and analytics will play in the future of our business, and the alternative investment industry as a whole. As the marketplace matures, demand for ‘better data’ will only continue to grow, and we are extremely well-positioned to support the market on this transformational journey. With technology running across the spectrum of our data solutions – from collection, to analytics, to delivery – we’re thrilled to be helping clients define the standards that will set their business on a solid foundation for sustainable future growth.”

Prior to joining Alter Domus in September 2021, Gus was a founding executive of Moody’s Analytics where he helped build several flagship products and services including Moody’s structured-finance products, ESG data and research services, Moody’s DataHub (DaaS), and other SaaS tools. Gus is a CPA and CFA charter holder and completed advanced degrees in finance from Columbia Business School, risk and statistics from New York University’s Stern School of Business, and technology from Pace University.

About Alter Domus

Alter Domus is a leading provider of integrated solutions, serving private equity, real assets and debt capital markets sectors with more than 3,600 employees across 36 offices globally. Solely dedicated to alternatives, Alter Domus offers fund administration, corporate services, depositary services, capital administration, transfer pricing, domiciliation, management company services, loan administration, agency services, trade settlement and CLO manager services. Find out more at www.alterDomus.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye